Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A germ cell tumor of the central nervous system occurring in children.
Biomarker and diagnostic research for childhood central nervous system germ cell tumor has been reported in the published literature.
2 clinical trials registered. Interventions under study include other interventions and procedural interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
170 publications have been identified in PubMed for childhood central nervous system germ cell tumor. Kisho has analyzed 104 by research type. Research spans Review / Meta-Analysis (48%), Basic Science / Preclinical (19%), and Gene Therapy / Novel Therapeutics (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 50 | 48% |
Laboratory research | 20 | 19% |
New treatment approaches | 12 | 12% |
Disease patterns and progression | 8 | 8% |
Testing and diagnosis research | 6 | 6% |
Clinical study results | 4 | 4% |
Patient case studies | 3 | 3% |
Other research | 1 | 1% |
Kardian AS (2026). [PMID: 41882368](https://pubmed.ncbi.nlm.nih.gov/41882368/). *Nature*. [Epidemiology / Natural History]
Mottolese C (2026). [PMID: 42115468](https://pubmed.ncbi.nlm.nih.gov/42115468/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]
Etezadi A (2026). [PMID: 41687521](https://pubmed.ncbi.nlm.nih.gov/41687521/). *Int Immunopharmacol*. [Review / Meta-Analysis]
Falcó-Roget J (2026). [PMID: 41099361](https://pubmed.ncbi.nlm.nih.gov/41099361/). *Neuro Oncol*. [Diagnostic / Biomarker]
Jaju A (2026). [PMID: 41274770](https://pubmed.ncbi.nlm.nih.gov/41274770/). *Neuroimaging Clin N Am*. [Review / Meta-Analysis]
Gauthier N (2026). [PMID: 41519468](https://pubmed.ncbi.nlm.nih.gov/41519468/). *World Neurosurg*. [Clinical Trial Publication]
O'Toole KT (2026). [PMID: 41752154](https://pubmed.ncbi.nlm.nih.gov/41752154/). *Int J Mol Sci*. [Review / Meta-Analysis]
McAlpine H (2026). [PMID: 41298888](https://pubmed.ncbi.nlm.nih.gov/41298888/). *Nat Neurosci*. [Basic Science / Preclinical]
Zhang J (2026). [PMID: 41882358](https://pubmed.ncbi.nlm.nih.gov/41882358/). *Nature*. [Basic Science / Preclinical]
Gudenas BL (2026). [PMID: 41791379](https://pubmed.ncbi.nlm.nih.gov/41791379/). *Cancer Cell*. [Basic Science / Preclinical]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:31 PM UTC
AI-curated news mentioning childhood central nervous system germ cell tumor
Updated Aug 22, 2026
A new strategic roadmap has been developed for conducting clinical trials in rare childhood central nervous system tumors, emphasizing the need for multi-stakeholder collaboration. This consensus aims to enhance trial delivery and improve outcomes for affected children.